Peter Kotanko

Dr. Peter Kotanko

1. Renal Research Institute, NEW YORK, NY, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2014 in Nature Reviews Nephrology
Verified
Journal Article
Closed access
PDF file
JKJeroen P. Kooman
Jeroen P. Kooman
Peter KotankoPeter Kotanko
Peter Kotanko
ASAnnemie M. W. J. Schols
Annemie M. W. J. Schols
PSPaul Shiels
Paul Shiels
PSPeter Stenvinkel
Peter Stenvinkel

27 January 2014 in Hemodialysis International
Verified
Journal Article
Closed access
PDF file
JSJeffrey J. Sands
Jeffrey J. Sands
LULen Usvyat
Len Usvyat
TSTerry Sullivan
Terry Sullivan
JSJonathan H. Segal
Jonathan H. Segal
PZPaul Zabetakis
Paul Zabetakis
JDJose A. Diaz‐Buxo
Jose A. Diaz‐Buxo

1 October 2017 in American Journal of Physiology-Renal Physiology
Verified
Journal Article
Closed access
PDF file
JKJeroen P. Kooman
Jeroen P. Kooman
MDMarijke J. Dekker
Marijke J. Dekker
LULen Usvyat
Len Usvyat
Peter KotankoPeter Kotanko
Peter Kotanko
FSFrank M. van der Sande
Frank M. van der Sande
PSPeter Stenvinkel
Peter Stenvinkel
Systemic inflammation in end-stage renal disease is an established risk factor for mortality and a catalyst for other complications, which are related to a premature aging phenotype, including muscle wasting, vascular calcification, and other forms of premature vascular disease, depression, osteoporosis, and frailty. Uremic inflammation is also mechanistically related to mechanisms involved in the aging process, such as telomere shortening, mitochondrial dysfunction, and altered nutrient sensing, which can have a direct effect on cellular and tissue function. In addition to uremia-specific causes, such as abnormalities in the phosphate-Klotho axis, there are remarkable similarities between the pathophysiology of uremic inflammation and so-called “inflammaging” in the general population. Potentially relevant, but still somewhat unexplored in this respect, are abnormal or misplaced protein structures, as well as abnormalities in tissue homeostasis, which evoke danger signals through damage-associated molecular patterns, as well as the senescence-associated secretory phenotype. Systemic inflammation, in combination with the loss of kidney function, can impair the resilience of the body to external and internal stressors by reduced functional and structural tissue reserves, and by impairing normal organ crosstalk, thus providing an explanation for the greatly increased risk of homeostatic breakdown in this population. In this review, the relationship between uremic inflammation and a premature aging phenotype, as well as potential causes and consequences, are discussed.

1 February 2015 in Kidney International
Verified
Journal Article
Open access
PDF file
ADAnke Dahlmann
Anke Dahlmann
KDKathrin Dörfelt
Kathrin Dörfelt
FEFlorian Eicher
Florian Eicher
PLPeter Linz
Peter Linz
CKChristoph Kopp
Christoph Kopp
JTJens M. Titze
Jens M. Titze
We have previously reported that sodium is stored in skin and muscle. The amounts stored in hemodialysis (HD) patients are unknown. We determined whether 23Na magnetic resonance imaging (sodium-MRI) allows assessment of tissue sodium and its removal in 24 HD patients and 27 age-matched healthy controls. We also studied 20 HD patients before and shortly after HD with a batch dialysis system with direct measurement of sodium in dialysate and ultrafiltrate. Age was associated with higher tissue sodium content in controls. This increase was paralleled by an age-dependent decrease of circulating levels of vascular endothelial growth factor-C (VEGF-C). Older (>60 years) HD patients showed increased sodium and water in skin and muscle and lower VEGF-C levels compared with age-matched controls. After HD, patients with low VEGF-C levels had significantly higher skin sodium content compared with patients with high VEGF-C levels (low VEGF-C: 2.3 <!----> ng/ml and skin sodium: 24.3 <!----> mmol/l; high VEGF-C: 4.1 <!----> ng/ml and skin sodium: 18.2 <!----> mmol/l). Thus, sodium-MRI quantitatively detects sodium stored in skin and muscle in humans and allows studying sodium storage reduction in ESRD patients. Age and VEGF-C-related local tissue-specific clearance mechanisms may determine the efficacy of tissue sodium removal with HD. Prospective trials on the relationship between tissue sodium content and hard end points could provide new insights into sodium homeostasis, and clarify whether increased sodium storage is a cardiovascular risk factor.

1 May 2010 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
SKSonal Korgaonkar
Sonal Korgaonkar
ATAnca Tilea
Anca Tilea
BGBrenda W. Gillespie
Brenda W. Gillespie
MKMargaret Kiser
Margaret Kiser
GEGeorge Eisele
George Eisele
RSRajiv Saran
Rajiv Saran
Background and objectives: The relationship between serum potassium (SK) and mortality in chronic kidney disease (CKD) has not been systematically investigated. Design, setting, participants, & measurements: We examined the predictors and mortality association of SK in the Renal Research Institute CKD Study cohort, wherein 820 patients with CKD were prospectively followed at four US centers for an average of 2.6 years. Predictors of SK were investigated using linear and repeated measures regression models. Associations between SK and mortality, the outcomes of ESRD, and cardiovascular events in time-dependent Cox models were examined. Results: The mean age was 60.5 years, 80% were white, 90% had hypertension, 36% had diabetes, the average estimated GFR was 25.4 ml/min per 1.73 m2, and mean baseline SK was 4.6 mmol/L. Higher SK was associated with male gender, lower estimated GFR and serum bicarbonate, absence of diuretic and calcium channel blocker use, diabetes, and use of angiotensin-converting enzyme inhibitors and/or statins. A U-shaped relationship between SK and mortality was observed, with mortality risk significantly greater at SK ≤4.0 mmol/L compared with 4.0 to 5.5 mmol/L. Risk for ESRD was elevated at SK ≤4 mmol/L in SK categorical models. Only the composite of cardiovascular events or death as an outcome was associated with higher SK (≥5.5). Conclusions: Although clinical practice usually emphasizes greater attention to elevated SK in the setting of CKD, our results suggest that patients who have CKD and low or even low-normal SK are at higher risk for dying than those with mild to moderate hyperkalemia.

1 May 2004 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
Peter KotankoPeter Kotanko
Peter Kotanko
RKReinhard Kramar
Reinhard Kramar
DDDanijela Devrnja
Danijela Devrnja
EPEduard Paschke
Eduard Paschke
TDTill Voigtla[Combining Diaeresis]Nder
Till Voigtla[Combining Diaeresis]Nder
MFManuela Födinger
Manuela Födinger
Anderson-Fabry disease is possibly underdiagnosed in patients with end-stage renal disease. Nationwide screening was therefore undertaken for Anderson-Fabry disease among dialysis patients in Austria. Screening for α-galactosidase A (AGAL) deficiency was performed by a blood spot test. In patients with a positive screening test, AGAL activity in leukocytes was determined. Individuals with decreased leukocyte AGAL activity were subjected to mutation testing in the GLA gene. Fifty (90.9%) of 55 Austrian hemodialysis centers participated in this study; 2480 dialysis patients (80.1% of the Austrian dialysis population) were screened. In 85 patients, the screening test was positive (85 of 2480, 3.42%; women, 3.32%; men, 3.50%). Among these 85 patients, 4 men (in 3 of whom Anderson-Fabry disease was already known before screening) had a severely decreased and 11 subjects had a borderline low AGAL activity. Genetic testing revealed mutations associated with Fabry disease in all four men with severely decreased AGAL activity resulting in a prevalence of 0.161% for the entire study population. A nationwide screening of dialysis patients permitted detection of a hitherto unknown man with Anderson-Fabry disease. The overall prevalence among dialysis patients was at least ten times higher as compared with recent registry data. Screening programs among patients with end-stage renal disease, especially men, should be put in place to identify families with Anderson-Fabry disease who probably may benefit from specific clinical care, and perhaps from enzyme replacement therapy. In dialysis patients, however, there is no evidence to support enzyme replacement therapy at present.